정신신체의학 (Korean Journal of Psychosomatic Medicine)

한국정신신체의학회 (Korean Psychosomatic Society)
권호 표지
DOI QR코드

DOI QR Code

폐경 단계에 따른 월경전 증후군/월경전 불쾌장애의 과거력과 혈관운동증상의 차별적 연관성

Differential Association of History of Premenstrual Syndrome/Premenstrual Dysphoric Disorder with Vasomotor Symptoms According to Menopausal Stage

  • 현홍대 (고려대학교 의과대학 정신건강의학교실) ;
  • 조숙행 (고려대학교 의과대학 정신건강의학교실) ;
  • 정현강 (고려대학교 의과대학 정신건강의학교실) ;
  • 고영훈 (고려대학교 의과대학 정신건강의학교실) ;
  • 권은주 (한국건강관리협회 건강증진연구소) ;
  • 김혜경 (한국건강관리협회 건강증진연구소) ;
  • 고승덕 (협성대학교 보건관리학과)
  • Hyun, Hong-Dae (Department of Psychiatry, Korea University College of medicine) ;
  • Joe, Sook-Haeng (Department of Psychiatry, Korea University College of medicine) ;
  • Jeong, Hyun-Ghang (Department of Psychiatry, Korea University College of medicine) ;
  • Ko, Young-Hoon (Department of Psychiatry, Korea University College of medicine) ;
  • Kwon, Eunjoo (Health Promotion Research Institute, Korea Association of Health Promotion) ;
  • Kim, Hyekyeong (Health Promotion Research Institute, Korea Association of Health Promotion) ;
  • Ko, Seung-Duk (Department of Health Management, Hyupsung University)
  • 투고 : 2015.05.14
  • 심사 : 2015.06.19
  • 발행 : 2015.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

연구목적 급격한 호르몬 변화가 발생하는 월경과 폐경 시기에 기분증상 및 신체증상이 나타난다는 공통된 임상적 특징과 생물학적 기전의 유사성을 바탕으로 하여 월경전 증후군/월경전 불쾌장애와 폐경기 증상의 연관성이 제기되었으나 아직까지 일관된 결론이 내려지지 않고 있다. 따라서 본 연구는 폐경기 여성에서 각각의 폐경 단계에 따라 월경 전 증후군의 과거력과 대표적인 폐경기 증상 중의 하나인 혈관운동증상의 연관성에 대해 조사해보고자 하였다. 방 법 한국건강관리협회 전국 16개 지사에 건강검진을 목적으로 방문한 361명의 폐경주위기 여성과 693명의 폐경후기 여성을 대상으로 단면연구를 시행하였다. 모든 대상자는 혈관운동증상과 월경전 증후군 과거력 및 여러 요인(연령, 결혼, 수입, 교육 수준, 음주, 운동, 흡연, 폐경에 대한 태도, 우울, 스트레스)에 대한 자가보고식 설문지를 작성하였다. 결 과 전기 폐경주위기를 제외한 후기 폐경주위기, 전기 폐경후기, 후기 폐경후기에서 월경전 증후군/월경전 불쾌장애의 과거력이 있는 여성에서 중등도 이상의 혈관운동증상을 호소하는 비율이 유의하게 높았다(전기 폐경주위기, p=0.824 ; 후기 폐경주위기, p=0.001 ; 전기 폐경후기, p=0.001 ; 후기 폐경후기, p=0.01). 후기 폐경주위기와 전기 폐경후기에서 PSST score와 혈관운동증상의 심각도가 유의한 양의 상관관계가 관찰되었다(후기 폐경주위기, r=0.213, p=0.010 ; 전기 폐경후기, r=0.246, p<0.001). 우울, 폐경에 대한 태도, 스트레스, 생활습관요인 등의 관련된 요인들을 통제하였을 때, 후기 폐경주위기와 전기 폐경후기에서 월경전 증후군/월졍전 불쾌장애의 과거력이 중등도 이상의 혈관운동증상을 예측하는 유의한 인자로 나타났다(후기 폐경주위기, OR=5.197, p=0.005 ; 전기 폐경후기, OR=3.017, p=0.010). 결 론 본 연구는 폐경 단계에 따라 월경전 증후군/월경전 불쾌장애와 혈관운동증상의 연관성이 차별적으로 나타남을 시사한다. 본 연구에서 나타난 결과를 규명하기 위한 추가적인 대단위의, 전향적인 연구가 필요할 것으로 사료된다.

Objectives:Within the normal reproductive cycles of women, dramatic fluctuations of sexual hormones occur in the premenstrual and menopausal periods. In both periods, women are vulnerable to mood disturbances and show several somatic complaints. Based on these common clinical profiles and physiological changes, a relationship between vasomotor symptoms and the premenstrual syndrome has been suggested. However, attempts to establish such a link have yielded inconclusive results. The purpose of this study was to investigate the association between histories of premenstrual syndrome and menopausal vasomotor symptoms within different menopausal stages. Methods:This cross-sectional study recruited Korean women aged 45-64 years who were perimenopausal and postmenopausal from 16 branch offices of the Korean Association of Health Promotion. All subjects completed self-report questionnaires that asked about a history of premenstrual syndromes, vasomotor symptoms, and several other variables. Results:A total of 1054 participants(361 perimenopausal women and 693 postmenopausal women) completed the study. Severity of premenstrual symptoms significantly correlated with postmenopausal vasomotor symptoms, only in late perimenopausal(r=0.213, p=0.010) and early postmenopausal women(r=0.246, p<0.001). After adjusting for several factors related to vasomotor symptoms, a history of premenstrual syndrome was a significant predictor of moderate to very severe vasomotor symptoms in late perimenopausal(OR=5.197, p=0.005) and early postmenopausal women(OR=3.017, p=0.010). Conclusions:This study suggests that a history of premenstrual syndrome/premenstrual dysphoric disorder is differentially associated with vasomotor symptoms in the menopausal stage. Prospective studies with larger population are needed to confirm these findings

키워드

참고문헌

  1. Payne JL, Palmer JT, Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harvard Review of Psychiatry 2009;17:72-86. https://doi.org/10.1080/10673220902899706
  2. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and Menopausal Status as Predictors of Depression in Womenin Transition to Menopause. Archives of General Psychiatry 2004;61:62-70. https://doi.org/10.1001/archpsyc.61.1.62
  3. Payne JL, Roy PS, Murphy-Eberenz K, Weismann MM, Swartz KL, McInnis MG, Nwulia E, Mondimore FM, MacKinnon DF, Miller EB. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. Journal of Affective Disorders 2007;99:221-229. https://doi.org/10.1016/j.jad.2006.08.013
  4. Richards M, Rubinow DR, Daly RC, Schmidt PJ. Premenstrual Symptoms and Perimenopausal Depression. American Journal of Psychiatry 2006;163:133-137. https://doi.org/10.1176/appi.ajp.163.1.133
  5. Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstetrics & Gynecology 2004;103:960-966. https://doi.org/10.1097/01.AOG.0000124804.81095.7f
  6. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The harvard study of moods and cycles. Archives of General Psychiatry 2006;63:385-390. https://doi.org/10.1001/archpsyc.63.4.385
  7. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews KA. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. American Journal of Public Health 2006;96:1226-1235. https://doi.org/10.2105/AJPH.2005.066936
  8. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. Journal of Affective Disorders 2003;74:67-83. https://doi.org/10.1016/S0165-0327(02)00432-9
  9. Sturdee DW. The menopausal hot flush-anything new? Maturitas 2008;60:42-49. https://doi.org/10.1016/j.maturitas.2008.02.006
  10. Steinberg S, Annable L, Young SN, Liyanage N. A placebocontrolled clinical trial of L-tryptophan in premenstrual dysphoria. Biological Psychiatry 1999;45:313-320. https://doi.org/10.1016/S0006-3223(98)00005-5
  11. Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology 2001;155:292-298. https://doi.org/10.1007/s002130100718
  12. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. The Lancet 2000;356:2059-2063. https://doi.org/10.1016/S0140-6736(00)03403-6
  13. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. Journal of Clinical Oncology 2005;23:6919-6930. https://doi.org/10.1200/JCO.2005.10.081
  14. Yonkers KA, O'Brien PS, Eriksson E. Premenstrual syndrome. The Lancet 2008;371:1200-1210. https://doi.org/10.1016/S0140-6736(08)60527-9
  15. Morse C, Dudley E, Guthrie J, Dennerstein L. Relationships between premenstrual complaints and perimenopausal experiences. Journal of Psychosomatic Obstetrics & Gynecology 1998;19:182-191. https://doi.org/10.3109/01674829809025696
  16. Hautamäki H, Haapalahti P, Savolainen-Peltonen H, Tuomikoski P, Ylikorkala O, Mikkola TS. Premenstrual symptoms in fertile age are associated with impaired quality of life, but not hot flashes, in recently postmenopausal women. Menopause 2014;21:1287-1291. https://doi.org/10.1097/GME.0000000000000247
  17. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: stages of reproductive aging workshop(STRAW). Climacteric 2001;4:267-272. https://doi.org/10.1080/cmt.4.4.267.272
  18. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool(PSST) for clinicians. Archives of Women's Mental Health 2003;6:203-209. https://doi.org/10.1007/s00737-003-0018-4
  19. Choi J, Baek JH, Noh J, Kim JS, Choi JS, Ha K, Kwon JS, Hong KS. Association of seasonality and premenstrual symptoms in bipolar I and bipolar II disorders. Journal of Affective Disorders 2011;129:313-316. https://doi.org/10.1016/j.jad.2010.07.030
  20. Heinemann LA, Potthoff P, Schneider HP. International versions of the menopause rating scale(MRS). Health and Quality of Life Outcomes 2003;1:28. https://doi.org/10.1186/1477-7525-1-28
  21. 이영호, 송종용. BDI, SDS, MMPI-D 척도의 신뢰도 및 타당도에 대한 연구. 한국심리학회지 임상 1991;10:98-113.
  22. Sommer B, Avis N, Meyer P, Ory M, Madden T, Kagawa-Singer M, Mouton C, Rasor NON, Adler S. Attitudes toward menopause and aging across ethnic/racial groups. Psychosomatic Medicine 1999;61:868. https://doi.org/10.1097/00006842-199911000-00023
  23. Avis NE, McKinlay SM. A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study. Maturitas 1991;13:65-79. https://doi.org/10.1016/0378-5122(91)90286-Y
  24. Cheng M-H, Wang S-J, Wang P-H, Fuh J-L. Attitudes toward menopause among middle-aged women: a community survey in an island of Taiwan. Maturitas 2005;52:348-355. https://doi.org/10.1016/j.maturitas.2005.06.001
  25. Frank SH, Zyzanski SJ. Stress in the clinical setting: the Brief Encounter Psychosocial Instrument. The Journal of Family Practice 1988:533-539.
  26. 임지혁, 배종면, 최순식, 김성원, 황환식, 허봉렬. 외래용 소트레스량 측정도구로서 한국어판 BEPSl 설문서(수정판)의 타당성. 가정의학회지 1996;17.
  27. Lee M-S, Kim J-H, Park MS, Yang J, Ko Y-H, Ko S-D, Joe S-H. Factors influencing the severity of menopause symptoms in Korean post-menopausal women. Journal of Korean Medical Science 2010;25:758-765. https://doi.org/10.3346/jkms.2010.25.5.758
  28. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstetrics & Gynecology 1996; 88:437-442. https://doi.org/10.1016/0029-7844(96)00196-2
  29. Rubinow DR, Schmidt PJ. The neuroendocrinology of menstrual cycle mood disorders. Annals of the New York Academy of Sciences 1995;771:648-659. https://doi.org/10.1111/j.1749-6632.1995.tb44717.x
  30. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine 1998;338:209-216. https://doi.org/10.1056/NEJM199801223380401
  31. Randolph Jr JF, Sowers M, Bondarenko I, Gold EB, Greendale GA, Bromberger JT, Brockwell SE, Matthews KA. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. The Journal of Clinical Endocrinology & Metabolism 2005;90:6106-6112. https://doi.org/10.1210/jc.2005-1374
  32. Deecher D, Dorries K. Understanding the pathophysiology of vasomotor symptoms(hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Archives of Women's Mental Health 2007;10:247-257. https://doi.org/10.1007/s00737-007-0209-5
  33. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opinion on Investigational Drugs 2005;14:435-448. https://doi.org/10.1517/13543784.14.4.435
  34. Freedman RR. Physiology of hot flashes. American Journal of Human Biology 2001;13:453-464. https://doi.org/10.1002/ajhb.1077
  35. Carlsson M, Carlsson A. A regional study of sex differences in rat brain serotonin. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1988;12:53-61. https://doi.org/10.1016/0278-5846(88)90061-9
  36. Hiroi R, McDevitt RA, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biological Psychiatry 2006;60:288-295. https://doi.org/10.1016/j.biopsych.2005.10.019
  37. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biological Psychiatry 1998;44:839-850. https://doi.org/10.1016/S0006-3223(98)00162-0
  38. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Frontiers in Neuroendocrinology 2002;23:41-100. https://doi.org/10.1006/frne.2001.0225
  39. Eriksson O, Wall A, Marteinsdottir I, Ågren H, Hartvig P, Blomqvist G, Langstrom B, Naessen T. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Research: Neuroimaging 2006;146:107-116. https://doi.org/10.1016/j.pscychresns.2005.02.012
  40. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. The International Journal of Psychiatry in Medicine 1993;23:1-27. https://doi.org/10.2190/J2W0-RTGD-NYKK-FF77
  41. Melke J, Westberg L, Landen M, Sundblad C, Eriksson O, Baghei F, Rosmond R, Eriksson E, Ekman A. Serotonin transporter gene polymorphisms and platelet [3 H] paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 2003;28:446-458. https://doi.org/10.1016/S0306-4530(02)00033-1
  42. Bachmann GA. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. The Journal of Reproductive Medicine 2005;50:155-165.
  43. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL, editors. Pathophysiology and Treatment of Hot Flashes. Mayo Clinic Proceedings;2002.
  44. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology 2002;20:1578-1583. https://doi.org/10.1200/JCO.20.6.1578
  45. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. The Journal of Clinical Endocrinology & Metabolism 2007;92:3060-3067. https://doi.org/10.1210/jc.2007-0066
  46. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ, Group SC. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. Fertility and Sterility 2012;97:843-851. https://doi.org/10.1016/j.fertnstert.2012.01.128
  47. Hall JE. Neuroendocrine physiology of the early and late menopause. Endocrinology and Metabolism Clinics of North America 2004;33:637-659. https://doi.org/10.1016/j.ecl.2004.08.002
  48. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008;15:603-612. https://doi.org/10.1097/gme.0b013e318174ea4d
  49. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Progress in Hormone Research 2002;57:257-276. https://doi.org/10.1210/rp.57.1.257
  50. Bromberger JT. A psychosocial understanding of depression in women: for the primary care physician. Journal of the American Medical Women's Association 2003;59:198-206.